Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S051 - Recent Advances in Bullous Diseases

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize and describe autoimmune bullous diseases
  • Outline treatment options for autoimmune bullous diseases
  • Describe co-morbidities associated with autoimmune bullous diseases


This Symposium features an international faculty who are experts in autoimmune bullous diseases and who have contributed to our body of knowledge in Dermatology on this subject. An overview of autoimmune bullous diseases will be presented and then selected current topics will be presented, some of which are controversial, that capture up-to-date information regarding the diagnosis and current treatment options of autoimmune bullous diseases. Treatment options for patients with autoimmune bullous diseases that are either IgG mediation or IgA mediated will be discussed including rituximab, IVIG, and standard immunosuppressive agents. Co-morbidities associated with selected autoimmune diseases will be discussed.


  • Ahmed, A. Razzaque, MD: no financial relationships exist with commercial interests.
  • Borradori, Luca, MD: no financial relationships exist with commercial interests.
  • Caux, Frederic, PhD: LEO Laboratories Ltd (LEO Pharma) – I(Fees); Novartis – A(H); Pierre Fabre Dermatologie – C(H); Principia Biopharma Inc – A(H), I(Fees); Roche Laboratories – I(Fees);
  • Diaz, Luis A., MD: no financial relationships exist with commercial interests.
  • Fairley, Janet A., MD: arGEN-X – C(NC); Immune Pharmaceuticals – I(Grants/Research Funding);
  • Joly, Pascal, MD, PhD: Almirall – C(H); GlaxoSmithKline – C(H); Lilly ICOS LLC – C(H); Novartis Pharmaceuticals Corp. – C(H); Principia Biopharma Inc – C(H); Roche Laboratories – C(H); sanofi-aventis – C(H);
  • Kasperkiewicz, Michael, MD: no financial relationships exist with commercial interests.
  • Prost Squarcioni, Catherine, MD: no financial relationships exist with commercial interests.
  • Woodley, David T., MD: no financial relationships exist with commercial interests.
  • Zone, John Joseph, MD: Principia Biopharma Inc. – I(NC);
Monday, February 19
9:00 AM
Dr. Woodley / Introduction
9:15 AM
Dr. Fairley / Overview of Autoimmune Bullous Diseases
9:30 AM
Dr. Caux / The Case Against Using IVIG Combined With Rituximab
9:45 AM
Dr. Ahmed / The Case for Using IVIG Combined With Rituximab
10:00 AM
Kasperkiewicz / The Correct Dosing of IVIG in Autoimmune Bullous Diseases
10:15 AM
/ Questions for Drs. Woodley, Fairley, Caux, Ahmed and Kasperkiewicz
10:30 AM
Dr. Joly / Modifications of Treatment Options for Autoimmune Bullous Disease Patients with Significant Co-Morbidities
10:45 AM
Dr. Borradori / The Association of Bullous Pemphigoid With Neurological Diseases - Facts, Myths and Theories
11:00 AM
Dr. Zone / Rituximab and Other Treatment Options for Recalcitrant IgA-Mediated Bullous Diseases
11:15 AM
Dr. Diaz / Update on Endemic Pemphigus Foliaceus
11:30 AM
/ Questions for Drs. Joly, Borradori, Zone and Diaz
11:45 AM
Dr. Prost Squarcioni / How To Make the Diagnosis of Epidermolysis Bullosa Acquisita (EBA)
11:59 AM
Event Details
  • Date
    Monday, February 19
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 25C
  • CME Credits
  • Type
  • David T. Woodley, MD, FAAD
  • A. Razzaque Ahmed, MD
  • Catherine Prost Squarcioni, MD
  • Frederic Caux, PhD
  • Janet A. Fairley, MD, FAAD
  • John Joseph Zone, MD, FAAD
  • Luca Borradori, MD
  • Luis A. Diaz, MD, FAAD
  • Michael Kasperkiewicz, MD
  • Pascal Joly, MD, PhD